Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01368 | NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT | 2857037-69-3 |
| NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a toxin payload in antibody drug conjugates that can inhibit topoisomerase I, and has good ADC activity in vivo and in vitro. | Inquiry | |
| BADC-01370 | Azonafide-PEABA | |
| Azonafide-PEABA is an ADC payload with potent DNA intercalation and topoisomerase inhibition activity. As an ADC cytotoxin, it facilitates precise delivery of cytotoxic effects in antibody-drug conjugates targeting aggressive tumors. | Inquiry | |
| BADC-01371 | 2',3'-cGAMP-C2-SH | 2133823-39-7 |
| 2',3'-cGAMP-C2-SH acts as an innovative ADC payload with immunomodulatory properties, facilitating immune activation in the tumor microenvironment. It serves as a unique ADC cytotoxin component to enhance immune-based cancer therapies via antibody-drug conjugates. | Inquiry | |
| BADC-01372 | INX-SM-6 | 2734878-16-9 |
| INX-SM-6 is a cytotoxic that can be used for targeted anti-inflammatory agent. INX-SM-6 inhibits human PBMCS producting LPS-induced IL-1β. | Inquiry | |
| BADC-01373 | Corixetan | 1952359-26-0 |
| Corixetan is an ADC cytotoxin payload that damages tumor cell DNA, promoting apoptosis. Used in antibody-drug conjugates, it enhances targeted drug delivery and efficacy in oncology treatments. | Inquiry | |
| BADC-01375 | CC-885-CH2-PEG1-NH-CH3 | 2722698-03-3 |
| CC-885-CH2-PEG1-NH-CH3 is a neoDegrader used in Antibody neoDegrader Conjugate (AnDC). | Inquiry | |
| BADC-01376 | INX-SM-56 | 2734878-18-1 |
| INX-SM-56 functions as a potent ADC payload inducing DNA crosslinking and cancer cell apoptosis. It is a valuable ADC cytotoxin for antibody-drug conjugates designed for high specificity and efficacy. | Inquiry | |
| BADC-01377 | Pyrrolobenzodiazepine (PBD) | 945490-09-5 |
| Pyrrolobenzodiazepines are a class of natural products with antibiotic or anti-tumor properties. They are produced by various actinomycetes. As a class of DNA-crosslinking agents, pyrrolobenzodiazepines are significantly more potent than systemic chemotherapeutic drugs. | Inquiry | |
| BADC-01379 | Eribulin | 253128-41-5 |
| Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21%, the time spent paused increased 67%, and dynamicity decreased 35% (but without reduction in mean centromere separation), indicating that eribulin decreased normal microtubule-dependent spindle tension at the kinetochores, preventing the signal for mitotic checkpoint passage. [(3)H]eribulin binds soluble tubulin at a single site; however, this binding is complex with an overall K(d) of 46 microM, but also showing a real or apparent very high affinity (K(d) = 0.4 microM) for a subset of 25% of the tubulin. Eribulin also binds microtubules with a maximum stoichiometry of 14.7 +/- 1.3 molecules per microtubule (K(d) = 3.5 microM), strongly suggesting the presence of a relatively high-affinity binding site at microtubule ends. At 100 nM, the concentration that inhibits microtubule plus end growth by 50%, we found that one molecule of eribulin is bound per two microtubules, indicating that the binding of a single eribulin molecule at a microtubule end can potently inhibit its growth. Eribulin does not suppress dynamic instability at microtubule minus ends. Eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation. | Inquiry | |
| BADC-01381 | Taltobulin hydrochloride | |
| Taltobulin hydrochloride (HTI-286 hydrochloride), a synthetic tripeptide cysteine analog, Taltobulin is a potent antimicrotubule that circumvents P-glycoprotein-mediated drug resistance in vitro and in vivo sex. Taltobulin hydrochloride inhibits purified tubulin polymerization, disrupts microtubule organization in cells, and induces mitotic arrest and apoptosis. | Inquiry | |
| BADC-01382 | Fmoc-MMAE | 474645-26-6 |
| Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE) and a potent tubulin inhibitor. | Inquiry | |
| BADC-01384 | Aminohexylgeldanamycin hydrochloride | 1146534-45-3 |
| Aminohexylgeldanamycin (AHGDM) hydrochloride, a derivative of Geldanamycin, is a heat shock protein 90 (HSP90) inhibitor. Aminohexylgeldanamycin hydrochloride has anti-angiogenic and anti-tumor activities. | Inquiry | |
| BADC-01385 | DC10SMe | |
| DC10SMe is a DNA alkylating agent useful in the synthesis of antibody drug conjugates (ADCs). DC10SMe has IC50 values of 15 pM, 12 pM and 12 pM against Ramos, Namalwa and HL60/s cancer cells, respectively. | Inquiry | |
| BADC-01386 | PROTAC BRD4 Degrader-9 | 2417370-42-2 |
| PROTAC BRD4 Degrader-9 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. It can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50 values of 0.86 nM and 7.6 nM, respectively. | Inquiry | |
| BADC-01387 | PROTAC BRD4 Degrader-12 | 2417370-90-0 |
| PROTAC BRD4 Degrader-12, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50s of 0.39 and 0.24 nM, respectively. | Inquiry | |
| BADC-01388 | PROTAC BRD4 Degrader-10 | 2417370-49-9 |
| PROTAC BRD4 Degrader-10, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50s of 1.3 and 18 nM, respectively. | Inquiry | |
| BADC-01389 | PROTAC BRD4 Degrader-11 | |
| PROTAC BRD4 Degrader-11 is a PROTAC linked by ligands for von Hippel-Lindau and BRD4. It is conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein in PC3 prostate cancer cells with DC50s of 0.23 nM and 0.38 nM, respectively. | Inquiry | |
| BADC-01390 | PROTAC BRD4 Degrader-13 | 2417370-71-7 |
| PROTAC BRD4 Degrader-13, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50s of 0.025 and 6.0 nM, respectively. | Inquiry | |
| BADC-01391 | Methotrexate monohydrate | 6745-93-3 |
| Methotrexate monohydrate is a DHhF reductase inhibitor that inhibits the enzyme dihydrofolate reductase and DNA synthesis. Therefore it is used to treat various cancers. | Inquiry | |
| BADC-01392 | 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,4-ethyl-4-hydroxy-9-methoxy-, (4S)- | 19685-10-0 |
| 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione acts as an advanced ADC linker that ensures stable conjugation between antibodies and cytotoxic payloads. It enhances antibody-drug conjugate stability and enables controlled drug release, boosting targeted cancer therapy effectiveness. | Inquiry |
